Forever Chemicals in Your Lotion and Sunscreen: What PFAS in Cosmetics Mean for Women’s Hormones

Why PFAS in cosmetics deserve a close look

“PFAS” (per- and polyfluoroalkyl substances) are a class of persistent synthetic chemicals often called “forever chemicals.” They are showing up in a range of personal care products — from shaving creams and sunscreens to moisturizers and hair products — and, because some PFAS can be absorbed or transferred across biological barriers, researchers and regulators have begun to examine whether cosmetic-derived exposure affects female reproductive hormones or developmental timing. This article summarizes the current evidence (as of 2026-05-04), what it means for hormone health, and practical steps you can take to reduce avoidable exposures.

Where PFAS turn up in cosmetics

Recent product inventories and chemical-chemistry studies estimate that thousands of kilograms of PFAS are present in cosmetics sold in large U.S. markets each year, with higher concentrations found in categories such as shaving products, hair products, cleansers, sun care, and lotions; makeup contains smaller mass overall but is not free of PFAS contamination (Environmental Science & Technology, 2024).

Modeling work also shows that cosmetics and other consumer products act as nonpoint sources of PFAS release across communities, meaning exposure is geographically widespread rather than limited to a single industrial site (ACS ES&T Water, 2024). National product-listing rules implemented under recent U.S. cosmetics legislation have given regulators more visibility: FDA’s MoCRA-mandated review identified dozens of distinct PFAS in a subset of listed cosmetic formulations nationwide (FDA PFAS report, Dec 29, 2025).

What the human-health studies show about hormones

Direct causal links between PFAS in cosmetics specifically and hormone-driven diseases have not been established, but epidemiology and biomonitoring studies provide biologically plausible concerns. Population cohort analyses have associated higher PFAS exposures with modest alterations in reproductive hormones and pubertal timing: some studies report changes in timing of pubarche/menarche and small shifts in hormones during the menopausal transition, consistent with PFAS acting on endocrine systems (HOME study & reviews, 2023) and (SWAN cohort analysis, J Clin Endocrinol Metab, 2021).

PFAS are also measurable in maternal serum and can transfer to breast milk at variable but detectable levels, which demonstrates a route for infant exposure during a hormonally sensitive window of development (Environmental Health Perspectives, 2023). Taken together, these lines of evidence support concern about PFAS exposures during vulnerable life stages (prenatal, infancy, puberty, perimenopause), though they do not prove that cosmetic use alone causes specific hormone-related diseases.

How PFAS could influence hormones (mechanisms and uncertainty)

Biologically, some PFAS can bind to or interfere with hormone receptors and hormone-regulating pathways in animal and cellular models; they are persistent and often slow to clear from the body, which raises the potential for accumulation from repeated topical use (Endocrine Society position). That said, human causal inference is limited by mixture exposures (people contact many chemicals across products), timing of exposure measurement, and the complexity of endocrine outcomes — so public-health guidance emphasizes precaution and better exposure reduction rather than definitive statements of cause-and-effect.

Regulatory and public-health context

Regulators in multiple jurisdictions are actively reassessing PFAS in consumer products. In the U.S., MoCRA’s product-listing requirements expanded FDA’s ability to see what’s on the market, and the agency’s recent PFAS report (Dec 2025) found dozens of PFAS in hundreds of formulations while also highlighting major data gaps about uses and safety (FDA PFAS report, Dec 29, 2025). National and international reviews are calling for improved testing, transparency, and limits where data indicate potential public-health risks (Health Canada overview, 2024).

Practical steps to reduce PFAS exposures from cosmetics

• Prioritize product types: Inventory studies show higher PFAS concentrations in some categories (shaving products, hair products, cleansers, sunscreens, lotions) — if you want to reduce exposure efficiently, start by reviewing and reducing use of these categories where feasible (EST, 2024).
• Check ingredient transparency: Look for full ingredient lists and avoid products that list vague “fluoro” ingredients, PTFE-related trade names, or ingredients you can’t identify; product disclosure has improved under MoCRA but gaps remain (FDA/MoCRA overview).
• Balance benefits and risks: For example, sunscreens provide documented benefits for skin cancer prevention; where possible choose physical/mineral sunscreens (zinc oxide, titanium dioxide) and avoid spray formats or products with poorly disclosed additives — weigh exposure reduction against clear health benefits (NIEHS, 2024).
• Limit product stacking: Using many products each day increases aggregate exposure. Simplifying your routine and choosing multifunction products with transparent labels can lower cumulative PFAS and other chemical load.

Bottom line

PFAS are present in some cosmetics and are of concern for hormone-sensitive windows because of their persistence and growing epidemiologic signals linking higher PFAS levels to modest hormone changes. The science does not yet tie routine cosmetic use conclusively to specific hormone disorders, but regulatory attention and biomonitoring data support a precautionary approach: reduce avoidable exposures, prefer products with clear labels, and follow evolving regulatory guidance. If you are pregnant, breastfeeding, planning pregnancy, or have a hormone-sensitive condition, discuss product choices with your clinician as part of overall exposure-reduction planning.

Key sources: peer-reviewed PFAS-in-cosmetics mass studies, recent FDA product-listing report, cohort analyses linking PFAS to reproductive hormones, and government health reviews (listed below).